Zejing pharmaceutical: an advance loss of 372 million yuan to 455 million yuan in 2021

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

China’s E-bike Brands Going Global: A Review of 26 Leading Players

With the global e-bike market continuing to expand, Chinese e-bike companies are gradually shifting from being a manufacturing powerhouse to becoming a meaningful force in global competition. This article reviews a group of Chinese e-bike players and examines their overseas positioning and market entry paths—looking at how Chinese brands are securing a foothold in the next wave of globalization.

EqualOcean Weekly Hotspots Series (8/17-8/22)

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

Meituan's Food Delivery Brand Keeta Launches in Qatar, Plans to Enter Brazil in Months

On August 19 (local time in Qatar), Keeta, the international food delivery brand under Chinese tech and retail giant Meituan, officially launched in Doha, the capital of Qatar. This marks another layout of Keeta in the Middle East market following its entry into Saudi Arabia.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.